1 / 20

Rapid Molecular Diagnostics of Antimicrobial Resistance

Rapid Molecular Diagnostics of Antimicrobial Resistance. Dr. Vicky Enne Centre for Clinical Microbiology Co-ordinator FP7 RiD -RTI PI Prof. Ali Zumla Co-I Dr. Vanya Gant. Talk Outline. Resistance problem & need for rapid diagnostics Complexity of resistance

marty
Download Presentation

Rapid Molecular Diagnostics of Antimicrobial Resistance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Rapid Molecular Diagnostics of Antimicrobial Resistance Dr. Vicky Enne Centre for Clinical Microbiology Co-ordinator FP7 RiD-RTI PI Prof. Ali Zumla Co-I Dr.Vanya Gant

  2. Talk Outline • Resistance problem & need for rapid diagnostics • Complexity of resistance • Potential benefit of rapid molecular diagnostics • Potential problems of rapid molecular diagnostics • Type of technologies • Examples of point of care systems on/near market • Technology in development at UCL – RiD-RTI • Knowledge gaps & future need

  3. Penicillin-resistant pneumococci vs. outpatient beta-lactam sales (From: Livermore. 2005. Lancet Infectious Diseases 5:450-459) The Problem of Antibiotic Resistance • Antibiotics used heavily in human & veterinary medicine • Use undoubtedly selects resistance • Multi-resistant organisms e.g. MRSA,VRE & C. difficile cause serious problems in hospital setting • Biggest current & future threat thought to come from Gram-negatives

  4. Complexity of Resistance Genetics in Gram-ve rods • Enormous complexity complicates both treatment and diagnosis • Resistance generally transmitted on mobile genetic elements – plasmids & transposons • Infection control needs to prevent not only spread of individual organisms but also genetic elements • Several different mechanisms for one resistance phenotype • e.g. at least 4 known for fluoroquinolones, can all be present at one • One bacterium / plasmid can carry a large number of different resistance genes – >10 commonplace

  5. Many variants of a single gene, sometimes with different phenotypes. (From: Cornagliaet al. Lancet Infect Dis 2011) There are approx. 30 distinct acquired beta-lactamase families, among these there can be up to 370 variants of a single type e.g. TEM, OXA (From: Canton et al. CMI 2012)

  6. The Need for Rapid Diagnostics • Conventional methods > 48h to identify antibiotic susceptibility • Reference laboratories often required to identify specific resistance gene – slows down outbreak tracing • Importance recognised in recent reports & policy documents (CMO Report, UK Strategy etc.)

  7. Potential Benefits of Rapid Diagnostics • Improved treatment outcome for patient • Improved infection control and outbreak monitoring achieved by acquiring more precise information sooner • Reduction in empirical antimicrobial prescriptions • Preservation of broad spectrum antimicrobials • Reduction in duration of treatment • Reduction in cost of treatment • Overall reduction antimicrobial consumption • Potential reduction in levels of resistance

  8. 8 years 3 years 2 years 8 years 7 months Does reduced prescribing reduce resistance? From: Enne 2010 JAC 65: 179-182

  9. Problems Associated with Molecular Diagnostics of Resistance • Discrepancy between genotype and phenotype • The potential presence of unknown resistance mechanisms leading to treatment failure • Genotypic markers of resistance not resulting in clinically significant resistance. Patient may be denied therapeutic drug needlessly. • Rapid molecular methods should be supplemented with culture-based techniques

  10. Sources of Pitfalls • Resistance gene not detected by test • PCR based technologies may not be able to include all possibilities – constantly changing epidemiology • New genes/mechanisms of resistance • Resistance genes not conferring resistance • Poorly expressed genes • Non-functional mutated genes • Silent genes • Difficulty in predicting exact resistance phenotype from genotype e.g. interplay of multiple simultaneous mechanisms e.g. low level efflux + mutations

  11. Technologies for Rapid Diagnostics • Point of care – near-patient systems requiring minimal user expertise • Kit-based – provides reagents but skilled operator & specialist equipment still required • PCR Based • Real-time/qPCR • Droplet PCR • Microarray – usually for 2ndary detection only • MALDI-TOF MS + PCR • Whole genome/next generation sequencing • Transcriptomics

  12. Point of Care Products on/near Market • Cepheid GeneXpert – Known for TB diagnostics, sample in answer out • CuretisUnyvero – sample in/answer out, pneumonia cartridge • NanosphereVerigene – sample in/answer out blood culture • Biofire (Biomerieux) FilmArray – blood culture • EpistemGenedrive – small, low cost. TB diagnostics.

  13. Cepheid GeneXpert • 1st point of care system introduced to market • MTB/RIF test, WHO endorsed • Good evaluation data • Integrated sample prep & PCR; cartridge based, < 1 hour • Low number of targets per test • Strong focus on colonisation/infection control • SA/MRSA testing from swabs or positive blood cultures • Carbapenemase assay from rectal swabs in pipeline (KPC, VIM, NDM)

  14. CuretisUnyVero Point of Care PCR based instrument. Test time < 4h Separate lysis unit First cartridge for pneumonia Comprehensive detection of bacterial pathogens , including those implicated in HAP & atypical infections Diverse list of resistance genes – mecA, macrolides, ESBLs, KPC, OXA-51, integron markers, FQR mutations Validation data not yet available

  15. NanosphereVerigene • Point of Care, PCR- based instrument • Works on positive blood cultures, < 2.5 h • Gram positive test • mecA, vanA, vanB • FDA cleared, generally good evaluation results but mis-ID of streptococci • Gram-negative test • KPC, NDM, IMP, VIM, CTX-M, OXA • No evaluation available yet

  16. In development at UCL – RiD-RTI • EU FP7 funded project to develop rapid diagnostics for respiratory tract infections • Low cost, point of care device • Integrated sample prep, cartridge based • PCR & microarray detection • Answer in < 2 hours • Ability to scale up

  17. Unique partnership of SMEs, Universities and Hospitals Sample Preparation & Real Time PCR assays Microarray chip design Clinical evaluation using patient samples Instrument & Software design

  18. 3 RTI Diagnostic products • Community acquired pneumonia • Bacteria vs. virus • Eliminates unnecessary empirical prescriptions • Resistance markers in phase 2 product • Hospital acquired pneumonia • S. aureus& enteric pathogens & non-fermenters • Comprehensive ESBL and carbapenamase • Opportunistic respiratory tract infections • Fungi, bacteria and virus

  19. What is Needed in the Future ? • Still in early stages of commercialisation – many tests not comprehensively validated yet • Many systems require regulatory approval - CE-IVD (Europe) & FDA (US) • Clinical evaluation of rapid diagnostics to guide treatment – will potential benefits be realised? • More comprehensive tests & scaleable devices • More focus on global problems, current devices heavily US based • More tests simultaneously • Ability of technology to adapt rapidly to evolving pathogens & emerging resistances

  20. Acknowledgements – RiD-RTI Consortium NUIG, Ireland Tom Barry Nina Tuite Kate Reddington Mobidiag, Finland JuhaKirveskari Genewave, France Francis Domain Yann Marcy Claude Weisbuch www.rid-rti.eu • UCL Ali Zumla (PI) LjubanGrgic Gareth Platt Stefan Schwenk YoannPersonne Mary Lenahan • UCLH Vanya Gant

More Related